AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 302 min read$PLUS

RAIGUEL DARREN S sold $188K of PLUS (indirect holdings)

RAIGUEL DARREN S (CHIEF OPERATING OFFICER) sold 2,000 indirectly-held shares of EPLUS INC (PLUS) at an average of $94.03 ($93.10–$95.35, $0.19M total) across 4 trades over 2026-07-28 to 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAIGUEL DARREN S
Published Jul 30, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PLUS
Neutral
high confidence
Mentioned
$PLUS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLUSNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may marginally influence sentiment, but it does not introduce new guidance, contracts, litigation, or operational metrics.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure limits actionable inference.

03

What to watch

The article specifies indirect holdings and a pre-arranged plan, which typically reduces interpretability versus discretionary sales.

Relevance 3/10Novelty 3/10Timing: Filed July 30, covering sales dated July 28 to July 29.

Background

This is an SEC Form 4 insider transaction disclosure for EPLUS INC (PLUS) by its COO, reported via SEC EDGAR.

Company-level read

Ticker impact

$PLUSNeutralHigh confidence
Context

EPLUS COO RAIGUEL DARREN S sold about 2,000 PLUS shares for roughly $188K under a pre-arranged 10b5-1 plan, filed July 30.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and the article contains no new company-specific operational or financial developments.

Market effects

Sector

No sector-level implications; this is a single-company insider transaction with no stated business catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated or sizable sales can still reflect personal liquidity needs or reduced conviction, which some traders may front-run.

Key entities

  • issuer
    PLUS

    EPLUS INC, the company whose insider transaction is disclosed.

  • insider
    RAIGUEL DARREN S

    Chief Operating Officer of EPLUS INC, selling shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Related articles

AUG 5
$PLUSMedAI 8/10

Why ePlus (PLUS) Shares Are Plunging Today

ePlus (NASDAQ: PLUS) shares fell about 5% after the company reported Q2 2026 results. Revenue rose 1.9% year over year to $649.1 million and adjusted EPS was $1.28, both above Wall Street estimates. Despite the beat, investors focused on declining adjusted operating and free cash flow margins and a forecast of about 2% full-year EPS growth. Shares later traded near $92.31.

financialcontent.com4 min
AUG 4
$PLUSMed

ePlus (NASDAQ:PLUS) Surprises With Q2 CY2026 Sales

ePlus (NASDAQ:PLUS) reported Q2 CY2026 revenue of $649.1 million, up 1.9% year on year, exceeding market expectations. Non-GAAP profit was $1.28 per share, 11.8% above analysts’ consensus. The company cited extended lead times and shipment delays tied to an ongoing memory chip shortage.

financialcontent.com4 min
AUG 4
$PLUSMed

EPLUS INC (PLUS): Results of Operations and Financial Condition

EPLUS INC (PLUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 ef20079242_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ePlus Reports First Quarter Fiscal Year 2027 Financial Results Managed Services Delivers Strong Performance and Increases Recurring Revenue ~ Reiterates Fiscal 2027 Guidance ~ First Quarter of Fiscal Year 2027 ● Net sales

SEC EDGAR 8-K6 min
AUG 4
$PLUSMed

ePlus Reports First Quarter Fiscal Year 2027 Financial Results

ePlus (NASDAQ: PLUS) reported Q1 FY2027 results for the three months ended June 30, 2026. Net sales rose 1.0% to $649.1 million and services revenue rose 2.6% to $119.4 million, while gross profit fell 1.5% to $151.3 million. Net earnings from continuing ops declined 5.4% to $30.3 million and adjusted EBITDA fell 9.2% to $47.8 million. The company reiterated FY2027 mid-single-digit growth guidance and declared a $0.27 quarterly dividend.

prnewswire.com6 min
JUL 13
$PLUSMed

PageGroup & Oxford Nanopore: Markets live

PageGroup shares rose over 11% after it reported Q2 gross profit of £198m, down 0.2% year on year but ahead of analyst expectations, and said it sees signs of market normalisation. ME Group International gained about 11% after interim results showed flat £154m sales. Plus500 shares fell on weaker cash margin, and Oxford Nanopore dropped 12% after H1 sales missed expectations at £116.5m.

investorschronicle.co.uk6 min